Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: Genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study

Authors

Jurjen Versluis, Harvard University
Peter Westervelt, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

10-1-2023

Volume

41

Issue

28

First Page

4497

Last Page

4510

Document Type

Open Access Publication

DOI

10.1200/JCO.23.00866

Rights and Permissions

Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, Horowitz M, Hourigan CS, Nakamura R, Cutler C, Lindsley RC; Blood and Marrow Transplant Clinical Trials Network. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. J Clin Oncol. 2023 Oct 1;41(28):4497-4510. doi: 10.1200/JCO.23.00866. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

Recommended Citation

Versluis, Jurjen; Westervelt, Peter; and et al., "Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: Genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study." Journal of Clinical Oncology. 41, 28. 4497 - 4510. (2023).
https://digitalcommons.wustl.edu/oa_4/3415

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.